Table 2. Association between selected clinicopathologic characteristics and estrogen receptor cERβ1 and nERβ2 staining in prostate cancer patients.
| cERβ1 | nERβ2 | |||||||
|---|---|---|---|---|---|---|---|---|
| None | Weak | Intense | None | Weak | Intense | |||
|
|
||||||||
| N (%) | N (%) | N (%) | p-value* | N (%) | N (%) | N (%) | p-value* | |
| 338 (66.4) | 52 (10.2) | 119 (23.4) | 387 (74.4) | 81 (15.6) | 52 (10.0) | |||
|
|
||||||||
| Age | ||||||||
| 35-49 | 48 (14.2) | 5 (9.6) | 10 (8.4) | 0.19 | 49 (12.7) | 11 (13.6) | 5 (9.6) | 0.5 |
| 50-54 | 60 (17.8) | 10 (19.2) | 26 (21.8) | 80 (20.7) | 13 (16.1) | 5 (9.6) | ||
| 55-59 | 78 (23.1) | 20 (38.5) | 30 (25.2) | 95 (24.5) | 19 (23.5) | 15 (28.8) | ||
| 60-64 | 94 (27.8) | 14 (26.9) | 38 (31.9) | 105 (27.1) | 24 (29.6) | 21 (40.4) | ||
| 65-69 | 39 (11.5) | 2 (3.8) | 8 (6.7) | 39 (10.1) | 7 (8.6) | 4 (7.7) | ||
| 70-74 | 19 (5.6) | 1 (1.9) | 7 (5.9) | 19 (4.9) | 7 (8.6) | 2 (3.9) | ||
| Race | ||||||||
| European-American | 306 (90.5) | 51 (98.1) | 108 (90.8) | 0.19 | 353 (91.2) | 76 (93.8) | 47 (90.4) | 0.71 |
| African-American | 32 (9.5) | 1 (1.9) | 11 (9.2) | 34 (8.8) | 5 (6.2) | 5 (9.6) | ||
| BMI | ||||||||
| <25 | 104 (30.8) | 16 (30.8) | 39 (32.8) | 0.61 | 127 (32.8) | 21 (25.9) | 16 (30.8) | 0.41 |
| 25-30 | 166 (49.1) | 27 (51.9) | 64(53.8) | 185 (47.8) | 48 (59.3) | 28 (53.8) | ||
| >30 | 68 (20.1) | 9 (17.3) | 16 (13.4) | 75 (19.4) | 12 (14.8) | 8 (15.4) | ||
| Stage | ||||||||
| Localized | 233 (68.9) | 41 (78.8) | 71 (59.7) | 0.04 | 266 (68.7) | 55 (67.9) | 30 (57.7) | 0.28 |
| Regional | 105 (31.1) | 11 (21.2) | 48 (40.3) | 121 (31.3) | 26 (32.1) | 22 (42.3) | ||
| Gleason Sum | ||||||||
| 2-6 | 165 (48.8) | 26 (50.0) | 51 (42.9) | 0.1 | 190 (49.1) | 38 (46.9) | 21(40.4) | 0.65 |
| 7 (3+4) | 130 (38.5) | 15(28.8) | 42 (35.3) | 142 (36.7) | 29 (35.8) | 20(38.5) | ||
| 7 (4+3)-10 | 43 (12.7) | 11 (21.2) | 26 (21.8) | 55 (14.2) | 14 (17.3) | 11(21.1) | ||
| PSA at diagnosis (ng/dL) | ||||||||
| 0-3.9 | 54 (16) | 7 (13.5) | 17 (14.3) | 0.21 | 53 (13.7) | 10 (12.3) | 13(25.0) | 0.38 |
| 4-9.9 | 202 (59.8) | 28 (53.8) | 68 (57.1) | 235 (60.7) | 48 (59.3) | 25(48.1) | ||
| 10-19.9 | 49 (14.5) | 8 (15.4) | 15 (12.6) | 50 (12.9) | 13 (16.1) | 8 (15.4) | ||
| 20+ | 14 (4.1) | 6 (11.5) | 12 (10.1) | 23 (5.9) | 6 (7.4) | 4 (7.7) | ||
| Unknown | 19 (5.6) | 3 (5.8) | 7 (5.9) | 26 (6.7) | 4 (4.9) | 2 (3.8) | ||
*
Univariate, Chi2